Company profile: Cancer Prevention Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of pharmaceutical agents and prevention therapies for people at elevated risk of cancer in the United States. Offers difluoro-methyl ornithine for clinical cancer prevention and treatment trials and develops diagnostic methods.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Cancer Prevention Pharmaceuticals
Attune Pharmaceuticals
HQ: United States
Website
- Description: Provider of biotechnology therapeutics, including ATN-249, an oral plasma kallikrein inhibitor for Hereditary Angioedema (HAE), and complement pathway inhibition approaches targeting the complement system to treat diseases such as Paroxysmal Nocturnal Hemoglobinuria (PNH).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Attune Pharmaceuticals company profile →
Anthera
HQ: United States
Website
- Description: Provider of products to treat diseases associated with inflammation and autoimmune diseases, including Vernis Soin, a nail polish that also acts as a treatment formulated with essential oils of lavender, tea tree, and geranium to nourish, fortify, and protect nails.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Anthera company profile →
Lung Therapeutics
HQ: United States
Website
- Description: Provider of pharmaceutical therapies targeting niche, orphan drug indications for lung injury and disease, with an emphasis on fibrosis. Pipeline includes LTI-03, a dual-mechanism dry powder inhaled treatment for idiopathic pulmonary fibrosis to improve lung function and reduce side effects, and LTI-01, a therapy for loculated pleural effusion that breaks down fibrous tissue to promote fluid drainage and alleviate symptoms.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lung Therapeutics company profile →
XORTX Therapeutics
HQ: Canada
Website
- Description: Provider of biopharmaceutical therapies for progressive kidney disease: XRx-008 for ADPKD to reduce cyst growth and improve kidney function; XRx-101 to lower uric acid for acute kidney injury and issues tied to serious viral infections, including COVID-19; and XRx-225, a pre-clinical treatment for Type 2 Diabetic Nephropathy targeting chronic kidney failure and end-stage kidney disease.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full XORTX Therapeutics company profile →
Acer Therapeutics
HQ: United States
Website
- Description: Provider of therapies for serious rare diseases, focused on acquiring, developing, and commercializing treatments. Portfolio includes OLPRUVA (U.S.-approved for urea cycle disorders) and investigational EDSIVO (vascular Ehlers-Danlos, COL3A1-positive), ACER-001 (Maple Syrup Urine Disease and other metabolic disorders), ACER-801 (vasomotor symptoms, PTSD), and ACER-2820 (host-directed therapy against viruses, incl. COVID-19).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Acer Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Cancer Prevention Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Cancer Prevention Pharmaceuticals
2.2 - Growth funds investing in similar companies to Cancer Prevention Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Cancer Prevention Pharmaceuticals
4.2 - Public trading comparable groups for Cancer Prevention Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →